JP2005538935A5 - - Google Patents

Download PDF

Info

Publication number
JP2005538935A5
JP2005538935A5 JP2003571482A JP2003571482A JP2005538935A5 JP 2005538935 A5 JP2005538935 A5 JP 2005538935A5 JP 2003571482 A JP2003571482 A JP 2003571482A JP 2003571482 A JP2003571482 A JP 2003571482A JP 2005538935 A5 JP2005538935 A5 JP 2005538935A5
Authority
JP
Japan
Prior art keywords
use according
cell
group
dosage form
oxygen species
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2003571482A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005538935A (ja
Filing date
Publication date
Priority claimed from US10/083,283 external-priority patent/US20030162837A1/en
Application filed filed Critical
Publication of JP2005538935A publication Critical patent/JP2005538935A/ja
Publication of JP2005538935A5 publication Critical patent/JP2005538935A5/ja
Withdrawn legal-status Critical Current

Links

JP2003571482A 2002-02-23 2003-02-20 カルボキシフラーレンおよびその使用方法 Withdrawn JP2005538935A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/083,283 US20030162837A1 (en) 2002-02-23 2002-02-23 Carboxyfullerenes and methods of use thereof
PCT/US2003/005332 WO2003072802A2 (en) 2002-02-23 2003-02-20 Carboxyfullerenes and methods of use thereof

Publications (2)

Publication Number Publication Date
JP2005538935A JP2005538935A (ja) 2005-12-22
JP2005538935A5 true JP2005538935A5 (https=) 2006-04-06

Family

ID=27753271

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003571482A Withdrawn JP2005538935A (ja) 2002-02-23 2003-02-20 カルボキシフラーレンおよびその使用方法

Country Status (6)

Country Link
US (1) US20030162837A1 (https=)
EP (1) EP1476150A4 (https=)
JP (1) JP2005538935A (https=)
AU (1) AU2003213206A1 (https=)
CA (1) CA2476782A1 (https=)
WO (1) WO2003072802A2 (https=)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7145032B2 (en) * 2002-02-23 2006-12-05 Washington University Therapeutic malonic acid/acetic acid C60 tri-adducts of buckminsterfullerene and methods related thereto
US20050058675A1 (en) * 2003-04-10 2005-03-17 Wilson Stephen R. Fullerene compositions for ameliorating dermatological conditions
US7163956B2 (en) * 2003-10-10 2007-01-16 C Sixty Inc. Substituted fullerene compositions and their use as antioxidants
US20050288236A1 (en) * 2003-10-10 2005-12-29 Russ Lebovitz Substituted fullerene formulations and their use in ameliorating oxidative stress diseases or inhibiting cell death
US20060247152A1 (en) * 2005-05-02 2006-11-02 Russ Lebovitz Substituted fullerenes and their use as inhibitors of cell death
WO2005058752A2 (en) * 2003-12-15 2005-06-30 Nano-C, Inc. Higher fullerenes useful as radical scavengers
WO2006028635A2 (en) * 2004-09-02 2006-03-16 C Sixty Inc. Fullerene compositions for ameliorating hearing loss, collateral damage of chemotherapy, or mucositis
JP2006160664A (ja) * 2004-12-07 2006-06-22 Vitamin C60 Bioresearch Kk フリーラジカル疾患予防治療用組成物
US20060188723A1 (en) * 2005-02-22 2006-08-24 Eastman Kodak Company Coating compositions containing single wall carbon nanotubes
US20070292622A1 (en) * 2005-08-04 2007-12-20 Rowley Lawrence A Solvent containing carbon nanotube aqueous dispersions
US20080020977A1 (en) * 2005-11-21 2008-01-24 Russ Lebovitz Use of Fullerenes to Oxidize Reduced Redox Proteins
US20090123893A1 (en) * 2007-06-08 2009-05-14 Alleman David S Method of performing and teaching adhesive dentistry
WO2009114089A2 (en) * 2008-03-03 2009-09-17 Luna Innovations Incorporated Using fullerenes to enhance and stimulate hair growth
JP2011513401A (ja) * 2008-03-03 2011-04-28 ルナ イノベーションズ インコーポレイテッド フラーレンを投与することにより動脈プラークの蓄積を抑制するための方法
US8598150B1 (en) 2008-04-02 2013-12-03 Jonathan R. Brestoff Composition and method for affecting obesity and related conditions
US8987245B2 (en) 2008-04-02 2015-03-24 Jonathan R. Brestoff Parker Composition and method for affecting obesity and related conditions
JP6216493B2 (ja) * 2011-06-24 2017-10-18 国立大学法人 香川大学 寿命延長剤
TN2011000327A1 (en) * 2011-06-30 2012-12-17 Fathi Moussa Fullerene and its use to maintain good health and to prolong the expected lifespan of mammals
US20200188339A1 (en) 2018-12-14 2020-06-18 Max Champie Nutraceutical Composition Comprising C60 And Ketone Esters
US11484508B2 (en) 2019-08-08 2022-11-01 Innovation for Success, LLC Dissolved C60 and method of producing dissolved C60
US10842742B1 (en) 2019-08-08 2020-11-24 Innovation for Success, LLC Dissolved C60 and method of producing dissolved C60
US11400113B2 (en) 2019-08-08 2022-08-02 Innovation for Success, LLC Dissolved C60 and method of producing dissolved C60
US12491209B2 (en) 2019-08-08 2025-12-09 Innovation for Success, LLC Dissolved C60 and method of producing dissolved C60
US12274713B2 (en) 2021-05-07 2025-04-15 Max C. Champie Nutraceutical composition comprising a water-soluble fullerene and a ketone

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4705781A (en) * 1986-10-08 1987-11-10 Giba-Geigy Corporation Method of treating cerebral ischemia using 4-(phosphono substituted lower alkyl or lower alkenyl)piperazine-2-carboxylic acids and salts, esters and amides thereof
JPH01316328A (ja) * 1988-06-15 1989-12-21 Mitsui Toatsu Chem Inc 老化防止、細胞賦活、老人病予防・治療のための薬剤
DE4313481A1 (de) * 1993-04-24 1994-10-27 Hoechst Ag Fullerenderivate, Verfahren zur Herstellung und deren Verwendung
US5648523A (en) * 1995-10-26 1997-07-15 Chiang Long Y Fullerene derivatives as free-radical scavengers
ATE190486T1 (de) * 1996-06-03 2000-04-15 Hoffmann La Roche Verwendung von buckminsterfulleren zur behandlung neurotoxischer verletzungen
US6265443B1 (en) * 1996-06-03 2001-07-24 Washington University Method for treating neuronal injury with carboxyfullerene
JP2001097888A (ja) * 1999-09-28 2001-04-10 Hiroshi Ikeno 外用組成物
TWI250874B (en) * 2000-03-24 2006-03-11 Nat Health Research Institutes Pharmaceutical compositions for preventing or treating disorders associated with bacterial or viral infection
CN1450905A (zh) * 2000-05-25 2003-10-22 法马顿股份有限公司 增强细胞保护的方法
US6538153B1 (en) * 2001-09-25 2003-03-25 C Sixty Inc. Method of synthesis of water soluble fullerene polyacids using a macrocyclic malonate reactant
US7145032B2 (en) * 2002-02-23 2006-12-05 Washington University Therapeutic malonic acid/acetic acid C60 tri-adducts of buckminsterfullerene and methods related thereto

Similar Documents

Publication Publication Date Title
JP2005538935A5 (https=)
WO2003072802A3 (en) Carboxyfullerenes and methods of use thereof
Kia et al. A first-principles study of functionalized clusters and carbon nanotubes or fullerenes with 5-Aminolevulinic acid as vehicles for drug delivery
JP2007504830A5 (https=)
US20160136167A1 (en) Use of 3-(5-amino-2-methyl-4-oxoquinazolin-3(4h)-yl)piperidine-2,6-dione in treatment of immune-related and inflammatory diseases
JP2010513314A5 (https=)
JP2010513363A5 (https=)
JP2008501615A5 (https=)
JP2008195730A5 (https=)
WO2006055747A3 (en) Bis(thio-hydrazide amides) for increasing hsp70 expression
JP2005526833A5 (https=)
MY137282A (en) New azabicyclic compounds, a process for their preparation and pharmaceutical compositions containing them.
Sundaramoorthy et al. Crystal structure and preliminary functional analysis of the cytochrome c peroxidase His175Gln proximal ligand mutant
JP2006502117A5 (https=)
Saikia Functionalized carbon nanomaterials in drug delivery: emergent perspectives from application
Shao et al. Utilizing reactive oxygen species-scavenging nanoparticles for targeting oxidative stress in the treatment of ischemic stroke: A review
Li et al. Lysine aggregates‐based nanostructured antimicrobial peptides for cariogenic biofilm microenvironment‐activated caries treatment
Myers et al. Insights into the mechanism of DNA cleavage by dynemicin A as revealed by DNA-binding and-cleavage studies of synthetic analogs
CA2476825A1 (en) Use of low molecular weight compounds for preparing a medicament useful in treating mutant p53 mediated diseases
Wang et al. Silver‐Based Nanozyme Hydrogel with Enhanced Multienzyme Activity for Infected Wound Treatment
JP2002542256A5 (https=)
WO2007073226A1 (en) Method for treating a mammal by administration of a compound having the ability to release co
JP2011516572A5 (https=)
Papageorgiou Enterohepatic Recirculation A Powerful Incentive for Drug Discovery in the Inosine Monophosphate Dehydrogenase Field
De Leon et al. Zigzag SWNT-amino acid interactions: Theoretical insights